Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 5

940 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
940
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

940 trials in Villejuif

Open in trial search

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Endometrial cancer+8

Recruiting

Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Rectal adenocarcinoma

Recruiting

Phase II Study of Intratumoral Hydrogen Peroxide (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydrogen peroxide
  • Sponsor:Institut Gustave Roussy

Sarcoma

Recruiting

Study of GSK5764227 Safety and Efficacy in Adults with Previously Treated Advanced Unresectable or Metastatic Sarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm

Recruiting

Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Recruiting

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:C4 Therapeutics Inc.

Study of ODM-212 in Combination with Cancer Treatment for Patients with Advanced Solid Tumours

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Orion Corporation

Non-small cell lung cancer stage III

Recruiting

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer stage IV

Recruiting

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.